Profectus BioSciences, Inc.
1450 South Rolling Road
Baltimore
Maryland
21227
United States
Tel: 443-543-5011
Fax: 443-543-5013
Website: http://www.profectusbiosciences.com/
47 articles about Profectus BioSciences, Inc.
-
CEPI Awards Contract Worth up to $36 Million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
8/16/2018
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD $36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1
-
Profectus BioSciences, Inc. Awarded NIH Contract For Up To $22.25 Million To Develop Multi-Component Vaccine For Ebola, Marburg, And Lassa Viruses
10/2/2017
-
Profectus BioSciences, Inc. Bivalent Vaccine Protects Animals From Infection And Death After Exposure To Chikungunya Or Zika Virus
1/9/2017
-
Profectus BioSciences, Inc. And Vyriad Form Global Collaboration To Develop Oncolytic Recombinant VSV (rVSV) Vaccines For Cancer Immunotherapy
3/18/2016
-
Profectus BioSciences, Inc. Initiates Ebola Vaccine Phase 1 Clinical Trial
1/19/2016
-
Profectus BioSciences, Inc. Receives $4.6 Million DOD Grant To Develop Vaccine For Western, Eastern, And Venezuelan Equine Encephalitis Viruses
12/9/2015
-
Profectus BioSciences, Inc. Presents Preclinical Data Demonstrating That A Single Dose Of Multi-Component Vaccine Provides Complete Protection Against Zaire And Sudan Species Of Ebola Virus And Marburg Virus
11/17/2015
-
Profectus BioSciences, Inc.' Ebola Vaccine Shown Effective And Safe In Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain In Non-Human Primates
4/9/2015
-
Profectus BioSciences, Inc. Nabs $9.5 Million Government Grant
10/31/2014
-
Ebola Clinical Trials: Big Name Players In The Ebola Race
10/28/2014
-
Profectus BioSciences, Inc. Receives Department Of The Army Funding For Studies Directed Toward The Development Of A VesiculoVax™ rVSV-Vectored Vaccine For Ebola And Marburg Viruses
10/22/2014
-
Profectus BioSciences, Inc. Receives $8.6 Million HHS Contract To Accelerate Ebola Vaccine Into Human Clinical Studies
10/22/2014
-
HHS Contracts With Profectus BioSciences, Inc. To Manufacture Ebola Vaccine For Animal Safety Studies
10/16/2014
-
Profectus BioSciences, Inc. Awarded $3.5M National Institutes of Health (NIH) SBIR Grants To Advance Therapeutic Vaccines Against HIV
7/29/2014
-
Profectus BioSciences, Inc. Presents Data at Filovirus Medical Countermeasures Meeting Showing That a Single Dose of VSV-Vectored Vaccine Completely Protects Monkey Against Challenge With Ebola and Marburg Viruses
9/24/2013
-
Profectus BioSciences, Inc. Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the “Cure Agenda”
9/17/2013
-
Althea Technologies, Inc. & Profectus BioSciences, Inc. Sign Manufacturing Agreement for Plasmid DNA Production
2/26/2013
-
Profectus BioSciences, Inc.'s Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial
12/4/2012
-
Profectus BioSciences, Inc. Receives $5.6M Grant to Develop a Vaccine to Protect Humans against Infection with Nipah/Hendra Viruses
5/9/2012
-
Profectus BioSciences, Inc. Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses
5/2/2012